natgillin/translations-raw huggingface dataset:
In order to allow for the eligibility of expenditure incurred and paid as from the date when the natural disaster occurred, even if that is before the entry into force of this Regulation, the corresponding provision on the starting date of eligibility of expenditure of beneficiaries should have retroactive effect.
U okviru zasebne prioritetne osi za prirodne katastrofe trebale bi se sufinancirati operacije kojima je cilj obnova nakon prirodnih katastrofa velikih razmjera ili regionalnih prirodnih katastrofa, kako su definirane u Uredbi Vijeća (EZ) br. 2012/2002 [5].
Regulation (EU) No 1303/2013 should be therefore amended accordingly,
Za operacije u okviru zasebne prioritetne osi za prirodne katastrofe potrebno je uvesti odstupanje od općih pravila u vezi s početnim datumom prihvatljivosti izdataka u vezi s izdacima koji postaju prihvatljivi slijedom izmjene programa kako bi se osigurala mogućnost sufinanciranja mjera koje su nadležna tijela država članica poduzela neposredno nakon katastrofe, a prije izmjene operativnog programa.
HAVE ADOPTED THIS REGULATION:
Kako bi se omogućila prihvatljivost izdataka koji su nastali i plaćeni od datuma kada se prirodna katastrofa dogodila, čak i ako je to prije stupanja na snagu ove Uredbe, odgovarajuća odredba o početnom datumu prihvatljivosti izdataka korisnika trebala bi imati retroaktivni učinak.
Article 1
Uredbu (EU) br. 1303/2013 trebalo bi stoga na odgovarajući način izmijeniti,
Amendment to Regulation (EU) No 1303/2013
DONIJELI SU OVU UREDBU:
In Article 120 of Regulation (EU) No 1303/2013, the following paragraph is added:
Članak 1.
A separate priority axis with a co-financing rate of up to 95 % may be established within an operational programme to support operations which fulfil all of the following conditions:
Izmjena Uredbe (EU) br.
the operations are selected by managing authorities in response to major or regional natural disasters as defined in Article 2(2) and (3) of Council Regulation (EC) No 2012/2002;
1303/2013
the operations are aimed at reconstruction in response to the natural disaster; and
U članku 120.
the operations are supported under an ERDF investment priority.
Uredbe (EU) br. 1303/2013 dodaje se sljedeći stavak:
The amount allocated to the operations referred to in the first subparagraph shall not exceed 5 % of the total ERDF allocation in a Member State for the 2014-2020 programming period.
Zasebna prioritetna os sa stopom sufinanciranja do 95 % može se utvrditi u operativnom programu za potporu operacijama koje ispunjavaju sve sljedeće uvjete:
By way of derogation from Article 65(9), expenditure for operations under this priority axis shall be eligible from the date when the natural disaster occurred.
operacije odabiru upravljačka tijela kao odgovor na prirodne katastrofe velikih razmjera ili regionalne prirodne katastrofe, kako su definirane u članku 2. stavcima 2. i 3.
Where expenditure in relation to operations referred to in the first subparagraph has been included in a payment application submitted to the Commission before the establishment of the separate priority axis, the Member State shall make the necessary adjustments to the next payment application and, where appropriate, to the next accounts submitted following the adoption of the amendment to the programme.
Uredbe Vijeća (EZ) br. 2012/2002;
Article 2
cilj je operacija obnova nakon prirodne katastrofe; i
Entry into force and application
operacije se podupiru u okviru investicijskog prioriteta EFRR-a.
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Iznos dodijeljen za operacije iz prvog podstavka ne smije premašiti 5 % ukupnih dodijeljenih sredstava EFRR-a u državi članici za programsko razdoblje 2014. – 2020.
Article 1 shall apply from 1 January 2014.
Odstupajući od članka 65. stavka 9., izdaci za operacije u okviru te prioritetne osi prihvatljivi su od datuma kada se dogodila prirodna katastrofa.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Ako su izdaci povezani s operacijama koje se navode u prvom podstavku uključeni u zahtjev za plaćanje podnesen Komisiji prije uspostave zasebne prioritetne osi, država članica na odgovarajući način prilagođava sljedeći zahtjev za plaćanje, a gdje je to primjereno i sljedeće podnesene račune nakon donošenja izmjene programa.
Done at Strasbourg, 4 July 2017.
Članak 2.
For the European Parliament
Stupanje na snagu i primjena
For the Council
Članak 1. primjenjuje se od 1. siječnja 2014.
OJ C 173, 31.5.2017, p.
Ova je Uredba u cijelosti obvezujuća i izravno se primjenjuje u svim državama članicama.
38.
Sastavljeno u Strasbourgu 4. srpnja 2017.
Position of the European Parliament of 13 June 2017 (not yet published in the Official Journal) and decision of the Council of 26 June 2017.
Za Europski parlament
Regulation (EU) No 1303/2013 of the European Parliament and of the Council of 17 December 2013 laying down common provisions on the European Regional Development Fund, the European Social Fund, the Cohesion Fund, the European Agricultural Fund for Rural Development and the European Maritime and Fisheries Fund and laying down general provisions on the European Regional Development Fund, the European Social Fund, the Cohesion Fund and the European Maritime and Fisheries Fund and repealing Council Regulation (EC) No 1083/2006 (OJ L 347, 20.12.2013, p.
Predsjednik
320).
Za Vijeće
Regulation (EU) No 1301/2013 of the European Parliament and of the Council of 17 December 2013 on the European Regional Development Fund and on specific provisions concerning the Investment for growth and jobs goal and repealing Regulation (EC) No 1080/2006 (OJ L 347, 20.12.2013, p.
SL C 173, 31.5.2017., str.
Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods [1], and in particular Article 18(5) thereof,
uzimajući u obzir Uredbu (EZ) br. 1924/2006 Europskog parlamenta i Vijeća od 20. prosinca 2006. o prehrambenim i zdravstvenim tvrdnjama koje se navode na hrani [1], a posebno njezin članak 18. stavak 5.,
Pursuant to Regulation (EC) No 1924/2006 health claims made on foods, as defined in that Regulation, are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.
Uredbom (EZ) br. 1924/2006 zdravstvene tvrdnje koje se navode na hrani, kako su definirane u toj Uredbi, zabranjuju se osim ako ih je odobrila Komisija u skladu s tom uredbom i uvrstila na popis dopuštenih tvrdnji.
Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State.
Uredbom (EZ) br. 1924/2006 predviđeno je i da subjekti u poslovanju s hranom mogu podnositi zahtjeve za odobrenje zdravstvenih tvrdnji nadležnom državnom tijelu države članice.
Following an application from Ecopharma BVBA, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Fabenol® Max, a standardised aqueous extract from Phaseolus vulgaris L., and the reduction of the absorption of carbohydrates (Question No EFSA-Q-2015-00123 [2]).
Na temelju zahtjeva trgovačkog društva Ecopharma BVBA, koji je podnesen u skladu s člankom 13. stavkom 5.
The claim proposed by the applicant was worded as follows: ‘Fabenol® Max reduces the absorption of carbohydrates’.
Uredbe (EZ) br. 1924/2006, zatraženo je mišljenje Agencije o zdravstvenoj tvrdnji koja se odnosi na Fabenol® Max, standardizirani vodeni ekstrakt graha Phaseolus vulgaris L., i smanjenje apsorpcije ugljikohidrata (predmet br. EFSA-Q-2015-00123 [2]).
On 23 February 2016, the Commission and the Member States received the scientific opinion from the Authority, which noted that the claimed effect was not sufficiently defined and that the applicant did not provide any further information as requested by the Authority.
Tvrdnja koju je predložio podnositelj zahtjeva glasila je kako slijedi: „Fabenol® Max smanjuje apsorpciju ugljikohidrata”.
Therefore, on the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the consumption of Fabenol® Max and the claimed effect.
Komisija i države članice primile su 23. veljače 2016.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Znanstveno mišljenje Agencije, koja je zaključila da učinak koji se navodi u tvrdnji nije dostatno definiran te da podnositelj zahtjeva nije dostavio dodatne informacije koje je Agencija zatražila.
Following an application from DSM Nutritional Products, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to docosahexaenoic acid (DHA) and improvement of memory function (Question No EFSA-Q-2015-00456 [3]).
Agencija je stoga na temelju dostavljenih podataka zaključila da nije utvrđena uzročno-posljedična veza između konzumiranja proizvoda Fabenol® Max i tvrdnje o njegovu učinku.
The claim proposed by the applicant was worded as follows: ‘DHA contributes to improved memory function’.
Stoga tu tvrdnju ne bi trebalo odobriti jer nije u skladu sa zahtjevima Uredbe (EZ) br. 1924/2006.
On 2 May 2016, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of DHA and the claimed effect.
Na temelju zahtjeva trgovačkog društva DSM Nutritional Products, koji je podnesen u skladu s člankom 13. stavkom 5.
Following an application from Tate & Lyle PLC, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to polydextrose and normal defecation (Question No EFSA-Q-2015-00550 [4]).
Uredbe (EZ) br. 1924/2006, zatraženo je mišljenje Agencije o zdravstvenoj tvrdnji koja se odnosi na dokosaheksaensku kiselinu (DHK) i bolje pamćenje (predmet br.
The claim proposed by the applicant was worded as follows: ‘Polydextrose contributes to an improved bowel function by increasing stool bulk’.
EFSA-Q-2015-00456 [3]).
On 25 May 2016, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of polydextrose and the claimed effect.
Tvrdnja koju je predložio podnositelj zahtjeva glasila je kako slijedi: „DHK pospješuje pamćenje”.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
Komisija i države članice primile su 2. svibnja 2016. znanstveno mišljenje Agencije, koja je zaključila da na temelju dostavljenih podataka nije utvrđena uzročno-posljedična veza između konzumiranja dokosaheksaenske kiseline i tvrdnje o njezinu djelovanju.
HAS ADOPTED THIS REGULATION:
Na temelju zahtjeva trgovačkog društva Tate & Lyle PLC, koji je podnesen u skladu s člankom 13. stavkom 5.
Article 1
Uredbe (EZ) br. 1924/2006, zatraženo je mišljenje Agencije o zdravstvenoj tvrdnji koja se odnosi na polidekstrozu i održavanje normalne defekacije (predmet br.
The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
EFSA-Q-2015-00550 [4]).
Article 2
Tvrdnja koju je predložio podnositelj zahtjeva glasila je kako slijedi: „Polidekstroza povećava volumen stolice i tako pospješuje rad crijeva”.
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Komisija i države članice primile su 25. svibnja 2016. znanstveno mišljenje Agencije, koja je zaključila da na temelju dostavljenih podataka nije utvrđena uzročno-posljedična veza između konzumiranja polidekstroze i tvrdnje o njezinu djelovanju.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Mjere predviđene ovom Uredbom u skladu su s mišljenjem Stalnog odbora za bilje, životinje, hranu i hranu za životinje,
Done at Brussels, 5 July 2017.
DONIJELA JE OVU UREDBU:
The President
Zdravstvene tvrdnje navedene u Prilogu ovoj Uredbi ne uvrštavaju se na popis dopuštenih tvrdnji Unije kako je predviđeno člankom 13. stavkom 3.
OJ L 404, 30.12.2006, p. 9.
Uredbe (EZ) br. 1924/2006.
EFSA Journal 2016;14(2):4401.
Članak 2.
EFSA Journal 2016;14(5):4455.
Ova Uredba stupa na snagu dvadesetog dana od dana objave u Službenom listu Europske unije.
EFSA Journal 2016;14(5):4480.
Ova je Uredba u cijelosti obvezujuća i izravno se primjenjuje u svim državama članicama.
ANNEX
Sastavljeno u Bruxellesu 5. srpnja 2017.
Rejected health claims
Za Komisiju
Application — Relevant provisions of Regulation (EC) No 1924/2006
Predsjednik
Nutrient, substance, food or food category
SL L 404, 30.12.2006., str. 9.
Claim
EFSA Journal 2016.;14(2):4401.
EFSA opinion reference
EFSA Journal 2016.;14(5):4455.
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
EFSA Journal 2016.;14(5):4480.
Fabenol® Max reduces the absorption of carbohydrates
PRILOG
DHA contributes to improved memory function
Odbijene zdravstvene tvrdnje
Polydextrose
Zahtjev – odgovarajuće odredbe Uredbe (EZ) br. 1924/2006
Polydextrose contributes to an improved bowel function by increasing stool bulk
Hranjiva tvar, tvar, hrana ili kategorija hrane
DHA
DHK pospješuje pamćenje.
Pursuant to Regulation (EC) No 1924/2006 health claims made on foodsare prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.
U skladu s Uredbom (EZ) br. 1924/2006 zabranjuje se navođenje zdravstvenih tvrdnji na hrani, osim ako je te tvrdnje odobrila Komisija u skladu s tom Uredbom i ako su uvrštene na popis dopuštenih tvrdnji.
Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State.
Uredbom (EZ) br. 1924/2006 predviđeno je i da subjekti u poslovanju s hranom mogu podnositi zahtjeve za odobrenje zdravstvenih tvrdnji nadležnom nacionalnom tijelu države članice.
Following an application from Beghin-Meiji and Tereos Syral, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to short-chain fructooligosaccharides from sucrose and maintenance of normal defecation (Question No EFSA-Q-2015-00377 [2]).
Na temelju zahtjeva trgovačkih društava Beghin-Meiji i Tereos Syral, koji je podneseni na temelju članka 13. stavka 5.
The applicant has proposed the following wording for the health claim: ‘maintain normal intestinal regularity’ or ‘maintain intestinal regularity by increasing the frequency of bowel movements’ or ‘contributes to normal intestinal regularity or normal bowel function’.
Uredbe (EZ) br. 1924/2006, zatraženo je mišljenje Agencije o zdravstvenoj tvrdnji povezanoj s djelovanjem kratkolančanih fruktooligosaharida iz saharoze i održavanjem normalne defekacije (Predmet br.
On 8 January 2016, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of short-chain fructooligosaccharides from sucrose and maintenance of normal defecation under the conditions of use proposed by the applicant.
EFSA-Q-2015-00377 [2]).
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Podnositelj zahtjeva predložio je sljedeći tekst za zdravstvenu tvrdnju: „održava normalan rad crijeva” ili „povećanjem učestalosti stolice održava normalan rad crijeva” ili „pridonosi normalnom radu crijeva ili normalnoj stolici”.
The comments from the applicant received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.
Komisija i države članice primile su 8. siječnja 2016. znanstveno mišljenje Agencije, koja je zaključila da na temelju dostavljenih podataka nije potvrđen uzročno-posljedični odnos između konzumacije kratkolančanih fruktooligosaharida iz saharoze i održavanja normalne defekacije u uvjetima uporabe koje je predložio podnositelj zahtjeva.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
Stoga tu tvrdnju ne bi trebalo odobriti jer nije u skladu sa zahtjevima iz Uredbe (EZ) br. 1924/2006.
HAS ADOPTED THIS REGULATION:
Pri određivanju mjera predviđenih ovom Uredbom Komisija je uzela u obzir primjedbe koje joj je dostavio podnositelj zahtjeva u skladu s člankom 16. stavkom 6.
Article 1
Uredbe (EZ) br. 1924/2006.
The health claim listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
Mjere predviđene ovom Uredbom u skladu su s mišljenjem Stalnog odbora za bilje, životinje, hranu i hranu za životinje,
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Zdravstvena tvrdnja navedena u Prilogu ovoj Uredbi ne uvrštava se na popis dopuštenih tvrdnji Unije kako je predviđeno člankom 13. stavkom 3.
Done at Brussels, 5 July 2017.
Uredbe (EZ) br. 1924/2006.
OJ L 404, 30.12.2006, p. 9.
Ova je Uredba u cijelosti obvezujuća i izravno se primjenjuje u svim državama članicama.
EFSA Journal 2016;14(1):4366.
Sastavljeno u Bruxellesu 5. srpnja 2017.
Rejected health claim
Predsjednik
Application — Relevant provisions of Regulation (EC) No 1924/2006
SL L 404, 30.12.2006., str. 9.
Nutrient, substance, food or food category
EFSA Journal 2016.;14(1):4366.
Claim
PRILOG
EFSA opinion reference
Odbijena zdravstvena tvrdnja
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Zahtjev – odgovarajuće odredbe Uredbe (EZ) br. 1924/2006
Short-chain fructooligosaccharides from sucrose
Hranjiva tvar, tvar, hrana ili kategorija hrane
Maintain normal intestinal regularity
Tvrdnja
Pursuant to Regulation (EC) No 1924/2006 health claims made on foods are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.
U skladu s Uredbom (EZ) br. 1924/2006 zdravstvene tvrdnje koje se navode na hrani zabranjene su osim ako ih je odobrila Komisija u skladu s tom Uredbom i ako su uvrštene na popis dopuštenih tvrdnji.
Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State.
Uredbom (EZ) br. 1924/2006 predviđa se i da subjekti u poslovanju s hranom mogu podnositi zahtjeve za odobravanje zdravstvenih tvrdnji nadležnom državnom tijelu države članice.
Following an application from Granarolo S.p.A., submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to a low-fat fermented milk with a combination of fructooligosaccharides and live Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) and Lactobacillus delbrueckii subsp. bulgaricus (LB2), and defence against reactivation of Herpes simplex virus in the orolabial epithelia (Question No EFSA-Q-2015-00488 [2]).
Na temelju zahtjeva trgovačkog društva Granarolo S.p.A., koji je podnesen na temelju članka 13. stavka 5.
The claim proposed by the applicant was worded as follows: ‘Consumption of low-fat fermented milk with a combination of fructo-oligosaccharides (FOS) and live Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) and Lactobacillus delbrueckii subsp. bulgaricus (LB2) helps to reduce recurrence of lip cold sores caused by Herpes simplex virus infection in healthy susceptible individuals’.
Uredbe (EZ) br. 1924/2006, zatraženo je mišljenje Agencije o zdravstvenoj tvrdnji povezanoj s fermentiranim mlijekom s niskim udjelom masti s kombinacijom fruktooligosaharida i živih kultura Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) i Lactobacillus delbrueckii subsp. bulgaricus (LB2) i obranom protiv reaktivacije virusa Herpes simplex na orolabijalnom epitelu (to jest na usnicama) (predmet br.
On 19 July 2016, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of the low-fat fermented milk, which was the subject of the health claim, and defence against reactivation of Herpes simplex virus in the orolabial epithelia.
EFSA-Q-2015-00488 [2]).
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Tvrdnja koju je predložio podnositelj zahtjeva glasi kako slijedi: „Konzumacija fermentiranog mlijeka s niskim udjelom masti s kombinacijom fruktooligosaharida (FOS) i živih kultura Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) i Lactobacillus delbrueckii subsp. bulgaricus (LB2) doprinosi smanjenju učestalosti ponovne pojave herpesa na usnama izazvanog infekcijom virusom Herpes simplex kod zdravih prijemljivih osoba”.
Following an application from Food for Health Ireland, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to FHI LFC24, a bovine milk-derived casein hydrolysate, and a reduction of post-prandial blood glucose responses (Question No EFSA- Q-2015-00755 [3]).
Komisija i države članice primile su 19. srpnja 2016. znanstveno mišljenje Agencije, koja j zaključila da na temelju iznesenih podataka nije utvrđena uzročno-posljedična veza između konzumacije fermentiranog mlijeka s niskim udjelom masti koje je bilo predmet zdravstvene tvrdnje i obrane protiv reaktivacije virusa Herpes simplex na orolabijalnom epitelu (to jest na usnicama).
The claim proposed by the applicant was worded as follows: ‘FHI LFC24 helps to regulate blood glucose levels following food consumption’.
Stoga tu tvrdnju ne bi trebalo odobriti jer nije u skladu sa zahtjevima Uredbe (EZ) br. 1924/2006.
On 22 July 2016, the Commission and the Member States received the scientific opinion from the Authority, which noted that the evidence provided by the applicant does not establish that a reduction in post-prandial glycaemic responses achieved by an increase in insulin secretion is a beneficial physiological effect for the target population of the claim.
Na temelju zahtjeva trgovačkog društva Food for Health Ireland, koji je podnesen u skladu s člankom 13. stavkom 5.
Therefore, on the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the consumption of the food subject to the claim and a beneficial physiological effect for the target population.
Uredbe (EZ) br. 1924/2006, zatraženo je mišljenje Agencije o zdravstvenoj tvrdnji koja se odnosi na proizvod FHI LFC24, hidrolizat kazeina dobiven iz mlijeka goveda, i smanjenje glikemijskog odgovora nakon obroka (predmet br.
Following an application from Pierre Fabre Medicament, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to V0137, a ‘DHA-enriched fish oil’, and ‘helps to slow the age-related cognitive decline in domains such as memory and executive function’ (Question No EFSA- Q- 2016-00071 [4]).
EFSA-Q-2015-00755 [3]).